Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anton Bespalov

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
European Journal of Pharmacology|April 6, 2010
Editorial for special issue on mGluRs and cognitionAnton Bespalov
Journal of Neuroscience Methods|November 7, 2017
Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?Anton Bespalov, Thomas Steckler
Biological Psychiatry|February 22, 2021
Pharmacology of Anxiety or Pharmacology of Elevated Plus Maze?Anton Bespalov, Thomas Steckler
Expert Opinion on Investigational Drugs|June 28, 2014
Development of novel therapy of schizophrenia in children and adolescentsCorinna Klein, Anton Bespalov
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 11, 2016
Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditionsAnton Bespalov, Liudmila Mus, Edwin Zvartau
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 23, 2019
Be positive about negatives-recommendations for the publication of negative (or null) resultsAnton Bespalov, Thomas Steckler, Phil Skolnick
Handbook of Experimental Pharmacology|November 8, 2019
Blinding and RandomizationAnton Bespalov, Karsten Wicke, Vincent Castagné
European Journal of Pharmacology|July 16, 2003
Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administrationSvetlana Semenova, Anton Bespalov, Athina Markou
Pharmacology, Biochemistry, and Behavior|November 21, 2024
Dusting off old blueprints: Is it time to reconsider metabotropic glutamate receptor 2 for therapeutic drug development?Anton Bespalov, Robert Lütjens, Dario Doller
Psychopharmacology|February 24, 2007
Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatmentSilke Harich, Gerhard Gross, Anton Bespalov
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
European Journal of Pharmacology|April 6, 2010
Editorial for special issue on mGluRs and cognitionAnton Bespalov
Journal of Neuroscience Methods|November 7, 2017
Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?Anton Bespalov, Thomas Steckler
Biological Psychiatry|February 22, 2021
Pharmacology of Anxiety or Pharmacology of Elevated Plus Maze?Anton Bespalov, Thomas Steckler
Expert Opinion on Investigational Drugs|June 28, 2014
Development of novel therapy of schizophrenia in children and adolescentsCorinna Klein, Anton Bespalov
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 11, 2016
Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditionsAnton Bespalov, Liudmila Mus, Edwin Zvartau
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 23, 2019
Be positive about negatives-recommendations for the publication of negative (or null) resultsAnton Bespalov, Thomas Steckler, Phil Skolnick
Handbook of Experimental Pharmacology|November 8, 2019
Blinding and RandomizationAnton Bespalov, Karsten Wicke, Vincent Castagné
European Journal of Pharmacology|July 16, 2003
Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administrationSvetlana Semenova, Anton Bespalov, Athina Markou
Pharmacology, Biochemistry, and Behavior|November 21, 2024
Dusting off old blueprints: Is it time to reconsider metabotropic glutamate receptor 2 for therapeutic drug development?Anton Bespalov, Robert Lütjens, Dario Doller
Psychopharmacology|February 24, 2007
Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatmentSilke Harich, Gerhard Gross, Anton Bespalov
Pageof 6